The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital, detailed his experience with patients treated with perampanel.
“As doctors, many times were asking about seizure numbers or side effects, and we’re maybe not getting all the other aspects of the disease.”
At the 73rd annual meeting of the American Epilepsy Society (AES), investigators presented additional data on perampanel (Fycompa; Eisai), an antiepileptic drug that has shown favorable retention rates and sustained efficacy for adolescents with partial-onset seizures during routine care. The PROVE study was conducted over a 24-month period, with more than 50% of enrolled patients seeing improvements in seizure freedom.
James Wheless, MD, professor of pediatric neurology, chief of pediatric neurology, and director of the comprehensive epilepsy program and Neuroscience Institute at Le Bonheur Children’s Hospital, was among the study investigators. He observed firsthand not only the long-term effects of perampanel on seizure freedom, but other improvements in real-world factors such as rates of hospitalization and non-seizure related problems.
Wheless sat down with NeurologyLive at AES 2019 to discuss the real-world results, and why perampanel may be a good first line therapy going forward.
For more coverage of AES 2019, click here.